Objective To investigate the effect of anti-angiogenic drug Bevacizumab and programmed cell death protein-1 (PD-L1) inhibitor Tislelizumab in the treatment of advanced non-small cell lung cancer (NSCLC). Methods From August 2019 to December 2020, 86 patients with advanced non-small cell lung cancer (NSCLC) treated in the third Department of Oncology, Xintai People′s Hospital were selected as subjects, the patients were divided into experimental group (43 cases) and control group (43 cases) according to the odd-even grouping method of admission number.Patients in the control group were treated with routine chemotherapy, while those in the experimental group were treated with Bevacizumab, an anti-angiogenic drug, and Tirizumab, a PD-L1 inhibitor. Before treatment and after 2 courses of treatment, the serological indexes (vascular endothelial growth factor [VEGF], insulin-like growth factor-1 [IGF-1],threonine kinase [AMPK]) and tumor markers (carcinoembryonic antigen [CEA], cytokeratin 19 soluble fragment[CYFRA21-1], alpha-fetoprotein [AFP]) were compared between the two groups. Before treatment and at 1, 2, and 3 weeks of treatment, the tumor volume (TV) was compared between the two groups. The survival conditions (median progression-free survival [mPFS], median overall survival [mOS]) and clinical treatment effect were compared between the two groups. Results After 2 courses of treatment, VEGF levels in the two groups were lower than those before treatment, IGF-1 and AMPK were higher than those before treatment in both groups, and VEGF and IGF-1 in the experimental group were lower than those in the control group,and AMPK was higher than that in the control group,and the differences were statistically significant (P＜0.05). After 2 courses of treatment, the levels of CEA, CYFRA21-1 and AFP in the two groups were lower than those before treatment, and CEA, CYFRA21-1 and AFP of the experimental group were lower than those of the control group, and the differences were statistically significant (P＜0.05). There were significant differences in time, intergroup and interaction between the two groups (P＜0.05). At 1, 2, and 3 weeks after treatment, the TV levels of the two groups were lower than those before treatment, and the TV of the experimental group was lower than that of the control group, and the differences were statistically significant (P＜0.05). PFS and OS of the experimental group were longer than those of the control group, and the differences were statistically significant (P＜0.05). There was no significant difference in ORR between the experimental group (46.51%) and the control group(27.90%) (P＞0.05). The DCR of experimental group (72.09%) was higher than that of control group (48.84%), and the difference was statistically significant (P＜0.05). Conclusion The combination therapy of advanced NSCLC with anti-angiogenic drug and PD-L1 inhibitors can reduce the level of tumor markers, improve serum parameters, reduce TV and prolong the survival time of patients.